Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.

Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. Gynecol Oncol. 2021 08; 162(2):375-381.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Benzimidazoles
Carboplatin
Data Interpretation, Statistical
Female
Humans
Neoplasm Grading
Ovarian Neoplasms
Paclitaxel
Reproducibility of Results
Research Design
Response Evaluation Criteria in Solid Tumors
Survival Analysis

authors with profiles

Gini Fleming